View More Recent Stories
-
Aptevo Therapeutics (APVO), Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
-
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
-
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
-
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
-
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
-
Aptevo Therapeutics (APVO) Announces 5.34M Share Offering at $0.515/sh
-
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
